improv outlook nutrit
come baxter earn two recur investor
question us nutrit weak recov
led downsid us medic deliveri manag confid
rebound address question detail note short answer
high degre confid acceler medic
deliveri slowdown nutrit less easi fix take longer
rebound neither item affect chang thesi name still
believ strong organ sale growth expand oper
margin lead ep upsid balanc sheet yet
deploy med-tech view ev/ebitda appropri valuat
metric baxter given lower leverag level vs peer
ev/ebitda ep vs peer continu see
potenti oper upsid multipl expans reiter ow
nutrit side busi shortfal caus
amino acid custom return pre-hurrican order
level background baxter essenti player amino acid
part compani macronutri busi macronutri
nutrit sale ww us
nutrit linger impact hurrican
led suppli disrupt baxter hospit ration limit amount
amino acid fed patient major custom
return normal purchas pattern baxter abl restor suppli
earlier year custom continu use reduc amino acid
level despit current avail go far repres
malpractic sizeabl bodi data support fact amino acid
supplement improv patient prognos
convert patient back regular purchas pattern take
time see growth improv sequenti expect
sale less wors us side easi comp off-set
slower convers remain custom look
expect custom convert back baxter even
easier comp caus headwind hurrican lead
growth low-double-digit rang still y/i ex-hurrican
dont see quick fix expect nutrit grow
easi comp modest improv util final
page analyst certif import disclosur
 morgan seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report singl
factor make invest decis
number move part within medic deliveri
resolv tight suppli mini-bag busi
compani unabl restor distribut partner back pre-hurrican suppli level
delay revenu pump busi custom slow purchas
anticip launch slower expect new patient add
large-volum parenter lvp busi
think biggest impact lack suppli svp mini-
bag ww busi mini-bag premix version
mini-bag requir reconstitut mini-bag busi ww
slower growth mini-bag line back full suppli
mini-bag product baxter fell short come
quarter manag feel confid mini-bag full
suppli septemb would provid better svp sale much
better
compani report morgan estim
shortfal lvp sale quarter stem slower
expect cadenc custom add quarter one main reason
come baxter commit long-term roll contract year
take longer negoti compani abl bring oem
earli juli guarante volum modest annual price increas
behind schedul also contribut quarterli shortfal new contract
repres annual sale ten million increment
growth total medic manag busi annual basi
signific chang lvp market dynam
delta vs initi plan baxter hasnt seen chang price
held share roughli flat led ytd growth comp
better compar initi plan manag plan
bring oem contract earlier braun came back
lvp suppli market probabl littl faster initi expect
didnt hear anyth concern rel baxter icu
earn last night competitor lvp svp svp icu fell short
goal due lower expect inventori level attempt serv
mani custom possibl shortag coupl self-inflict
product challeng stem ramp volum
resolv lvp icu made concert effort shift volum
trading-ori market baxter doesnt particip price
higher volum less certain long-term contract lower rate
mention gain share slow market growth combin
clariti provid manag give us confid
lastli infus system busi baxter clear line sight
improv revenu growth follow launch infus
typic order instal time month there suppli
constraint baxter end place mani order receiv rather
bottleneck hospit end particularli slower summer month
baxter recogn revenu pump sale fulli instal
provid long clear line sight acceler base
number contract alreadi sign yet fulli instal
high degre confid acceler medic
deliveri slowdown nutrit less easi fix take
longer rebound neither item affect chang thesi name
still believ strong organ sale growth expand oper
margin lead ep upsid plu one balanc sheet yet
deploy med-tech view ev/ebitda appropri valuat
metric baxter given lower leverag level vs peer
ev/ebitda ep vs peer continu see
potenti oper upsid multipl expans reiter ow
invest thesi valuat risk
baxter turnaround stori play better expect think there
still plenti room go sinc take januari ceo almeida
transform compani low-margin low-fcf busi one that
significantli under-lev gener signific vs
expand oper margin two year
baxter today top-lin growth busi see upsid potenti
opportun achiev margin expans next five year
driven mix upgrad gross margin improv exist busi
control oper spend that without put work underleverag
balanc sheet debt use drive earn power
either accret larg share buyback neither seem
reflect street model backdrop reiter overweight
rate stock
dec price target valu stock cash ep
ev/ebitda premium peer trade cash
ep ev/ebitda believ ev/ebitda appropri
metric due baxter lower leverag level vs peer also believ premium
ep warrant due compani compar top-lin outlook
above-p ep compound-annual-growth-rate upsid potenti capit alloc
risk rate price
downsid risk includ manag inabl deliv margin
expans target misalloc balanc sheet potenti
reimburs price cut
baxter summari financi
cash equival
flow oper activ
o/w chang work capit
flow invest activ
sale
flow financ activ
net chang cash
adj free cash flow firm
compani report morgan estim
note million except per-shar data fiscal year end dec o/w
analyst certif research analyst denot ac cover report certifi multipl research
analyst primarili respons report research analyst denot ac cover within document
individu certifi respect secur issuer research analyst cover research view
express report accur reflect person view subject secur issuer part
research analyst compens directli indirectli relat specif recommend view
express research analyst report korea-bas research analyst list front cover also certifi per
kofia requir analysi made good faith view reflect opinion without undu influenc
